This restoration promotes the infiltration of CD8+ T cells into tumor sites, and when paired with anti‐PD‐1 therapy, induces a robust and durable anti‐tumor response.[30] Additionally, HDAC8‐specific inhibitors can ameliorate the immunosuppressive TME by modulating the transcription of the NKG2D ligand gene. The gene discussed is PDCD1; the disease is neoplasm.